Technology

Avidea is leveraging innovations in polymer–drug conjugate (PDC) technologies to usher in an era of safer and more effective ‘precision immunotherapies.’

Our approach

Many promising immunotherapies inadequately reach target tissues leading to dose-limiting toxicities and low efficacy. Avidea’s PDC platforms address this challenge by shielding drug molecules during transit through the body and targeting them to specific cells where activity is needed. What distinguishes Avidea’s PDCs is that each enables precise and truly unparalleled control over key parameters that affect safety, efficacy and manufacturability

Modular design

for rapid hypothesis testing and hit-to-lead
Uniform nanoparticles

with programmable, high drug loading (up to 60%m/m)
Targeting

to specific tissue and cell populations not limited by antigen expression
Controlled drug release

for improved therapeutic index

Avidea's PDC platforms

SNAPvax™

Modular vaccine capable of co-delivering any antigen(s) and immunomodulator(s) in self-assembling nanoparticles with precise size and composition
Most efficient T cell priming platform reported to-date
Applications: cancer, autoimmunity and infectious diseases

Syntholytic™

Synthetic, virus-sized star polymer combines direct tumor killing with immune stimulation, akin to oncolytic viruses, without the drawbacks
Dual responsive properties for targeted accumulation and selective drug release in tumor
Applications: metastatic tumor targeting

TRAPD™

Nanoparticle formation occurs after injection thereby trapping drug in tissues where it is needed
Reduced dosing frequency enabled by low viscosity (< 100 cP) of highly concentrated (> 100 mg/mL) drug in nanoparticles (~ 50 nm) retained at injection site
Applications: retains drugs in the eye, CNS and joints

Technology

Our approach

Modular design

Uniform nanoparticles

Targeting

Controlled drug release

Avidea's PDC platforms

SNAPvax™

Syntholytic™

TRAPD™